Caitong International Asset Management’s Capricor Therapeutics CAPR Stock Holding History

Caitong International Asset Management’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,519	Closed	-$76.6K	–	3038
2026 Q1	$76.6K	Buy	+2,519	New	+$67.1K	0.01%	658
2025 Q3	–	Sell	-138	Closed	-$1.37K	–	1999
2025 Q2	$1.37K	Sell	138 -22,357	-99%	-$236K	﹤0.01%	1498
2025 Q1	$213K	Buy	22,495 +22,372	+18,189%	+$311K	0.16%	111
2024 Q4	$1.7K	Buy	+123	New	+$2.15K	﹤0.01%	1201

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Caitong International Asset Management's CAPR Position: Q2 2026 in Review

Caitong International Asset Management sold out of Capricor Therapeutics (CAPR) in Q2 2026, closing a stake of 2,519 shares — an estimated $76.6K sold.

Caitong International Asset Management first reported a position in CAPR in Q4 2024 and held it in 4 quarters. The position peaked at $213K in Q1 2025. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

Caitong International Asset Management reported no remaining Capricor Therapeutics position as of Q2 2026 after selling out during the quarter.
Caitong International Asset Management sold 2,519 Capricor Therapeutics shares in Q2 2026, an estimated $76.6K.
Caitong International Asset Management first reported a position in Capricor Therapeutics in Q4 2024 and held it in 4 quarters.
Caitong International Asset Management's Capricor Therapeutics position peaked at $213K in Q1 2025.
169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.